This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| CD86 | |
|---|---|
| Name | CD86 |
| Other names | B7-2, B70 |
| Uniprot | P42081 |
| Organism | Human |
CD86 is a 70 kDa type I transmembrane glycoprotein expressed on antigen-presenting cells and various hematopoietic lineages. It functions as a costimulatory molecule that modulates T cell activation, tolerance, and the balance between immune activation and suppression. CD86 is closely related to other immunoregulatory proteins and has been studied across contexts including transplantation, autoimmunity, and cancer.
CD86 is encoded by a gene located on human chromosome 21, in proximity to loci studied in cytogenetics and genomics initiatives such as the Human Genome Project and International HapMap Project. The protein belongs to the immunoglobulin superfamily and contains extracellular IgV-like and IgC-like domains, a single transmembrane helix, and a short cytoplasmic tail implicated in intracellular trafficking. Structural characterization has employed techniques from the Protein Data Bank and crystallographic studies similarly used for CTLA4 and CD28 family members. Comparative genomics with orthologs in Mus musculus and other model organisms informed evolutionarily conserved residues and glycosylation sites identified by Glycobiology methods.
CD86 expression is inducible on professional antigen-presenting cells such as Dendritic cell subsets, Macrophage populations, and activated B cells; it is also reported on endothelial cells and certain epithelial contexts studied in Pathology and Immunopathology research. Expression is upregulated by pattern recognition receptor signaling pathways triggered by ligands recognized by Toll-like receptors, and by cytokines including Interferon gamma and Tumor necrosis factor alpha, which are central to inflammatory signaling cascades characterized in immunology and cell biology. Transcriptional and post-translational regulation involve factors and complexes studied in Transcription factor research, ubiquitination machinery characterized in Proteasome pathways, and trafficking routes traced with methods from Confocal microscopy and Flow cytometry.
CD86 provides a critical second signal for naive and memory T lymphocytes during antigen presentation by interacting with receptors on T cells identified in adaptive immunity research. The balance of CD86-mediated costimulation versus inhibitory inputs shapes outcomes observed in Graft-versus-host disease models, Autoimmune disease models such as studies of Systemic lupus erythematosus and Rheumatoid arthritis, and vaccination responses examined in Clinical trial cohorts. CD86 influences T helper cell polarization documented in Th1 and Th2 differentiation literature, regulatory T cell function studied in FOXP3 research, and cytotoxic T lymphocyte priming assessed in Cancer immunology investigations.
CD86 binds to at least two receptors on T cells: one stimulatory receptor and one inhibitory receptor, both of which have been central to immune checkpoint biology widely studied alongside PD-1 and CTLA4. Engagement of CD86 with the costimulatory receptor promotes signaling cascades involving kinases and adaptor proteins characterized in T cell receptor signaling maps and common to studies of Lck and ZAP-70. Interaction with the inhibitory receptor modulates phosphatase recruitment pathways described in research on SHP-1 and SHP-2, altering downstream transcriptional programs involving NF-κB and AP-1. Cross-talk between CD86-mediated signals and pathways activated by pattern recognition receptors, cytokine receptors such as IL-2 receptor, and metabolic regulators explored in mTOR studies integrates CD86 function into broader cellular networks.
Altered CD86 expression or function is implicated in diverse clinical settings including transplant rejection studied in Organ transplantation literature, chronic infections such as HIV/AIDS cohorts, and tumor immune evasion described in Oncology research. Polymorphisms and expression quantitative trait loci near the CD86 locus have been analyzed in genome-wide association studies conducted by consortia like International HapMap Project and disease-specific consortiums. Therapeutic modulation of CD86 influences outcomes in preclinical models of Multiple sclerosis and Type 1 diabetes, and clinical correlations have been reported in prognostic studies across hematologic malignancies and solid tumors evaluated at cancer centers such as Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center.
CD86 is a target or biomarker in therapeutic strategies that include blockade or agonism within immune checkpoint modulation paradigms pioneered in Cancer immunotherapy and Transplant immunology. Clinical-grade biologics and fusion proteins inspired by mechanisms studied for CTLA4-Ig and monoclonal antibodies have been evaluated in trials registered by agencies like the Food and Drug Administration and regulators in multinational programs. Combination approaches integrating CD86 modulation with vaccines assessed in Vaccine research or with small-molecule inhibitors developed in pharmaceutical pipelines at firms and academic spinouts leverage insights from translational immunology initiatives such as those led by National Institutes of Health and collaborative networks. Future directions draw on synthetic biology, chimeric antigen receptor platforms developed at institutions including University of Pennsylvania, and systems immunology frameworks exemplified by projects like the Human Cell Atlas.
Category:Immune system proteins